RIPK3 and Alzheimer disease: We observed that loss of RIPK3 did not significantly alter amyloid deposition and gliosis in 5xFAD mice, which, despite components of the necroptotic signaling pathway being reportedly activated in AD (15), argues for RIPK3 not appearing to appreciably affect Aβ amyloidosis in 5xFAD mice.